Pharmacokinetic and Tolerance Study in Healthy Participants: a Single-centre, Randomized, Double-blind, Placebo-controlled Trial
Latest Information Update: 02 Jul 2020
At a glance
- Drugs TQ A3326 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 09 Dec 2018 Status changed from not yet recruiting to recruiting.
- 30 Oct 2018 New trial record